This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999; 32: 545–552.
Attygalle A, Al Jehani R, Diss TC, Munson P, Liu H, Du MQ et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 2002; 99: 627–633.
Scappaticci FA . Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906–3927.
Dogan A, Ngu LSP, Ng SH, Cervi PL . Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia 2005; 19: 873–875.
Gasparini G, Longo R, Fanelli M, Teicher B . Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005; 23: 1295–1311.
Hurwitz H, Fehrenbacher L, Cartwright T . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legres L et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004; 84: 1512–1519.
Wang E, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MAS . Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893–2902.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bruns, I., Fox, F., Reinecke, P. et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 19, 1993–1995 (2005). https://doi.org/10.1038/sj.leu.2403936
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403936
This article is cited by
-
Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy
Current Hematologic Malignancy Reports (2018)
-
Molecular genetics of peripheral T-cell lymphomas
International Journal of Hematology (2014)
-
From empiric to mechanism-based therapy for peripheral T cell lymphoma
International Journal of Hematology (2014)